Therapeutic Goods Amendment Regulation 2012 (No. 2)

Administered by Department of Health, Disability and Ageing

Legislation au F2012L01455 Regulations Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

Select Legislative Instrument 2012 No. 143

 

Therapeutic Goods Act 1989

 

Therapeutic Goods Amendment Regulation 2012 (No. 2)

 

Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2)

 

The object of the Therapeutic Goods Act 1989 (the Act) is to establish and maintain a national system of controls for the quality, safety, efficacy and timely availability of therapeutic goods that are used in Australia or exported from Australia.  The Therapeutic Goods Administration (the TGA), which is part of the Department of Health and Ageing, is responsible for administering the Act.   

 

Subsection 63(1) of the Act provides that the Governor-General may make regulations, not inconsistent with the Act, prescribing matters required or permitted to be prescribed by the Act, or necessary or convenient to be prescribed for carrying out or giving effect to the Act. 

 

The purpose of the regulations is to amend the Therapeutic Goods Regulations 1990 (the TG Regulations) and the Therapeutic Goods (Medical Devices) Regulations 2002 (the MD Regulations) to increase most fees set out in those regulations by 5.6 per cent.

The 5.6 per cent increase reflects both a 3.6 per cent increase in TGA fees and charges based on a formula agreed with industry associations (comprised of 50 per cent of the Labour Price Index to September 2011 and 50 per cent of the Consumer Price Index to September 2011), and an additional increase of two per cent.  The additional two per cent increase reflects the need to fund the implementation of a number of recommendations arising from several recent reviews into key areas of the regulation of therapeutic goods, and to improve TGA’s capacity to conduct post market surveillance of therapeutic goods.

 

These reviews and recommendations are outlined in the TGA document TGA reforms: A Blueprint for TGA’s future, dated December 2011 and include measures relating to the improvement of regulatory transparency (such as the development of consultation principles, and the release of a wider range of information relating to the regulation of therapeutic goods), complementary medicines (including updating guidelines relating to the levels and kinds of evidence supporting therapeutic claims made about those products that should be held by sponsors), medical devices (including the reclassification of certain kinds of joint replacement devices) and advertising  of therapeutic products. 

 

The fees increases relating to the TG Regulations apply to application fees for registration or listing on the Australian Register of Therapeutic Goods (the Register), application fees for manufacturing licences, evaluation fees, clinical trial notification fees, application fees for export certificates and inspection fees for manufacturing premises.

 

The fees increases relating to the MD Regulations apply to fees relating to conformity assessments and abridged conformity assessments of medical devices, applications for the inclusion of medical devices in the Register and conformity assessment certificates for medical devices.

 

 

In applying these increases, the following rounding policy has been applied:

a)      for amounts that are less than $140, up to the nearest $10;

b)     for amounts between $141 and $10,000, to the nearest $10; and

c)      for amounts over $10,000, to the nearest $100.

 

The amendments to the TG Regulations and MD Regulations, when taken together with the changes to the Therapeutic Goods (Charges) Regulations 1990, are expected to increase the fees and charges collected by the TGA by $2.6 million (to $120.5 million) over the 2012-13 financial year.

 

The increases enable the TGA to recover its costs in administering the Act and continue to meet the Government’s Cost Recovery Guidelines, and support the implementation of the reforms process and improvements mentioned above.

 

Details of the amendments to the TG Regulations are set out in Attachment A and details of the changes to the MD Regulations are set out in Attachment B.

 

Consultations with industry associations, including in relation to the proposal to increase TGA fees and charges by 5.6 per cent, were held at sectoral bilateral meetings convened between 21 and 24 February 2012.  Industry was not supportive of an increase of 5.6 per cent, as it exceeded the 3.6 percent increase that would be made based solely on the indexation model relating to annual increases of TGA fees and charges agreed between industry and the TGA.

 

The Act specifies no conditions that need to be met before the power to make the regulations may be exercised.

 

The regulations are legislative instruments for the purposes of the Legislative Instruments Act 2003.

 

The regulations commence on 1 July 2012.

 

 

Authority:  Subsection 63(1) of the Therapeutic Goods Act 1989

 

3

ATTACHMENT A

 

Details of the Therapeutic Goods Amendment Regulation 2012 (No. 2)

 

Section 1 – Name of regulation

This section provides for the regulation to be referred to as the Therapeutic Goods Amendment Regulation 2012 (No. 2).

 

Section 2 – Commencement

This section provides for the regulation to commence on 1 July 2012.

 

Section 3 – Amendment of Therapeutic Goods Regulations 1990

This section provides for Schedule 1 to amend the Therapeutic Goods Regulations 1990 (the TG Regulations).

 

Schedule 1 – Amendments

 

Item [1] - Table of amendments – fees

 

Item [1] increases various fees specified in paragraph 43AAJ(1)(b) and subregulations 45(4A), 45(9) and 45(11) of the TG Regulations, and in Parts 2 and 2A of Schedule 9 to the TG Regulations, by 5.6 per cent, subject to the TGA’s rounding policy.

 

In addition, item [1] replaces the reference in regulation 45A of the TG Regulations to $13 000 with a reference to $14 000. This threshold amount is determined based on the value of 100 units of the fee payable under Schedule 9, Part 2, item 3AB.  That fee is currently $130, but will increase to $140 as part of the general increase of TGA fees to be effected by item [1]. The increase of the threshold amount therefore reflect the related fee increase.

 


4

ATTACHMENT B

 

Details of the Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2)

 

Section 1 – Name of regulation

This section provides for the regulation to be referred to as the Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2).

 

Section 2 – Commencement

This section provides for the regulation to commence on 1 July 2012.

 

Section 3 – Amendment of Therapeutic Goods Regulations 1990

This section provides for Schedule 1 to amend the Therapeutic Goods (Medical Devices) Regulations 2002 (the MD Regulations).

 

Schedule 1 – Amendments

 

Item [1] – Table of amendments – fees

 

This item increases the fee for an abridged conformity assessment, in paragraph 9.4(2)(b) of the MD Regulations, by 5.6 per cent, subject to the TGA’s rounding policy.

 

This item also increases the fees for all relevant items in Part 1 of Schedule 5 to the MD Regulations by 5.6 per cent, subject to the TGA’s rounding policy.

 

Part 2 of Schedule 5 to the MD Regulations currently provides for additional fees for assessments that are required to be conducted outside Australia. These fees are currently calculated at a rate of $340 for each hour of preparation by each assessor involved.

 

This item increases the fee of $340 per hour of preparation by each assessor currently payable under paragraph 2.1 (b) of Part 2 of Schedule 5 to the MD Regulations, by 5.6 per cent, subject to the TGA’s rounding policy, to $360.


5

Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

 

Therapeutic Goods Amendment Regulation 2012 (No. 2)

 

This legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

 

Overview of the Legislative Instrument

The Therapeutic Goods Amendment Regulation 2012 (No. 2) (the Amendment Regulation) is made under subsection 63(1) of the Therapeutic Goods Act 1989.

The purpose of the Amendment Regulation is to amend the Therapeutic Goods Regulations 1990 to increase most fees set out in those regulations by 5.6 per cent, subject to the Therapeutic Goods Administration’s rounding policy.  The increase in fees applies to application fees for registration or listing on the Australian Register of Therapeutic Goods, application fees for manufacturing licences, evaluation fees, clinical trial notification fees, application fees for export certificates and inspection fees for manufacturing premises.

 

Human rights implications

This legislative instrument does not engage any of the applicable rights or freedoms.

 

Conclusion

This legislative instrument is compatible with human rights as it does not raise any human rights issues.

 

 

 

Catherine King

Parliamentary Secretary for Health and Ageing

 

Overview

The Therapeutic Goods Amendment Regulation 2012 (No. 2) and the Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2) were enacted to amend the Therapeutic Goods Regulations 1990 and the Therapeutic Goods (Medical Devices) Regulations 2002 respectively, by increasing most fees associated with these regulations by 5.6 per cent. These amendments were made under the authority of subsection 63(1) of the Therapeutic Goods Act 1989, which allows the Governor-General to make regulations to carry out or give effect to the Act. The primary objective of these regulations is to adjust the fees charged by the Therapeutic Goods Administration (TGA) to reflect a 3.6 per cent increase based on the Labour Price Index and the Consumer Price Index, and an additional two per cent increase to fund recent TGA reforms and enhance post-market surveillance of therapeutic goods. These reforms include measures to improve regulatory transparency, update guidelines for complementary medicines, reclassify certain medical devices, and regulate the advertising of therapeutic products. The fee increases are expected to raise the total fees and charges collected by the TGA by $2.6 million to $120.5 million in the 2012-13 financial year, enabling the TGA to meet its cost recovery obligations and implement the aforementioned reforms. The regulations were developed following consultations with industry associations, although industry feedback indicated a preference for a lower fee increase than the one ultimately implemented. The Therapeutic Goods Amendment Regulation 2012 (No. 2) and the Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2) commenced on 1 July 2012, and are legislative instruments under the Legislative Instruments Act 2003. These regulations were deemed compatible with human rights as they do not engage any of the applicable rights or freedoms outlined in the Human Rights (Parliamentary Scrutiny) Act 2011.

Scope and Application

The Therapeutic Goods Act 1989 applies to all therapeutic goods used in or exported from Australia, with the aim of ensuring their quality, safety, efficacy, and timely availability. The Therapeutic Goods Administration, part of the Department of Health and Ageing, administers the Act. The Act enables the Governor-General to make regulations that are not inconsistent with the Act, necessary, or convenient for its execution. The Therapeutic Goods Amendment Regulation 2012 (No. 2) and the Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2) increase most fees set out in the Therapeutic Goods Regulations 1990 and the Therapeutic Goods (Medical Devices) Regulations 2002 by 5.6 per cent, reflecting a combination of indexation and additional funding for reforms. These amendments apply to fees for registration, manufacturing licences, evaluations, clinical trials, exports, inspections, conformity assessments, and inclusion in the Australian Register of Therapeutic Goods. The increases are subject to the Therapeutic Goods Administration's rounding policy and are intended to support the agency's cost recovery and reform initiatives. The regulations commenced on 1 July 2012 and are compatible with human rights as they do not raise any human rights issues.

Key Provisions

The Therapeutic Goods Amendment Regulation 2012 (No. 2) and the Therapeutic Goods (Medical Devices) Amendment Regulation 2012 (No. 2) (collectively, the "Regulations") primarily serve to amend the Therapeutic Goods Regulations 1990 and the Therapeutic Goods (Medical Devices) Regulations 2002, respectively. These Regulations increase most fees associated with the registration, listing, evaluation, and inspection of therapeutic goods and medical devices by 5.6%, in line with the Therapeutic Goods Act 1989 (the "Act") and the Therapeutic Goods Administration's (TGA) rounding policy. Specifically, the Regulations impact application fees for registration or listing on the Australian Register of Therapeutic Goods (the "Register"), manufacturing licences, evaluation fees, clinical trial notification fees, export certificates, conformity assessments, and inspections of manufacturing premises. Entities and individuals governed by these Regulations must comply with the new fee structures. For instance, those applying for registration or listing of therapeutic goods on the Register, seeking manufacturing licences, or requiring evaluation of their products must now account for the increased fees. Similarly, holders of medical device conformity assessments and those requiring inspections of their manufacturing premises must adjust their budgets to reflect the higher costs. The Act does not specify particular offences or penalties for non-compliance with these Regulations. However, failure to adhere to the fee structures or other regulatory requirements could lead to broader consequences under the Act, such as delays in approvals, fines, or other enforcement actions by the TGA. The increased fees are intended to fund the implementation of regulatory reforms and improvements in post-market surveillance, ensuring that the TGA can continue to maintain high standards for the quality, safety, and efficacy of therapeutic goods and medical devices in Australia.

Legal classification tags

Area of Law
Regulatory Standards
Regulatory & Substantive — select at least one
Instrument
Regulation
Concepts
Fees & Charges
Compliance Obligations
Regulatory Standards
Catchwords
Fees Adjustment

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.